Brendon Neuen's Publications

About Brendon Neuen's Publications

Senior Research Fellow, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

    The Lancet Diabetes & Endocrinology Date published:

  • The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials

    Heart, Lung and Circulation Date published:

  • Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:

  • Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

    Circulation Date published:

  • An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes

    Diabetes, Obesity and Metabolism Date published:

  • Reframing Chronicity with Urgency in Chronic Kidney Disease Management

    Clinical Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:

  • Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

    Nephrology Dialysis Transplantation Date published:

  • Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:

  • Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure

    Journal of the American College of Cardiology Date published:

  • Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Chronic Kidney Disease Progression in Heart Failure

    JACC: Heart Failure Date published:

  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

    Clinical Journal of the American Society of Nephrology Date published:

  • Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease

    Circulation Date published:

  • Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia

    Diabetes, Obesity and Metabolism Date published:

  • SGLT2 INHIBITORS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH DIABETES AT HIGH RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HEART FAILURE OR CHRONIC KIDNEY DISEASE: A SMART-C COLLABORATIVE META-ANALYSIS

    Journal of the American College of Cardiology Date published: